Candel Therapeutics at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Candel Therapeutics brings 2 presentations to PEGS Europe 2026 in Lisbon. Its program centres on immunotherapy for solid tumours and where clinical outcomes in the field stand. It presents aglatimagene besadenovec (CAN-2409) as a multimodal biological immunotherapy.

OrganizationPEGS Europe 2026 Attendance
candeltx.com
Biotech
Clinical-stage company developing viral immunotherapies for solid tumours, led by the adenovirus-based aglatimagene besadenovec (CAN-2409).
Talk
Thu Nov 19
2:05pm–2:35pm
Panel
Thu Nov 19
3:35pm–4:15pm
Clinical Outcomes in Immunotherapy—Where Are We Now?
Next-Generation Immunotherapies · with Accession Therapeutics, BioInvent, Immatics +2 more

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Candel Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction